TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Recall of health-related information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Static compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: specificity to sexual stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resistance to movement artifacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correspondence with subjective measures of sexual arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean arterial pressure peak increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate peak increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neurocognitive Function (NCF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient-Reported Outcomes (PRO)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: log CFU reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: positive culture rate for Gram-positive bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: aneurysm rupture or aneurysm-related death
Endpoint domain: Mortality/survival
Primary endpoint: Elimination clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumes of the central compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumes of the shallow peripheral compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of uncovered struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prevalence of clinical and subclinical autoimmune diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical improvements measured by HAM-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life improvements measured by QLI
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: venous thromboembolic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Urea reduction ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Creatinine reduction ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: FGF23 clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase in weekly average number of CSBMs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in Bristol stool character
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in PAC-QOL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CGI-C score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HC gp39 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of affected joints (NAJ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma AUC of tacrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent oral clearance of tacrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Wound area of limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound area of torso
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for getting information of wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of 90° knee flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tHcy plasmatic concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone healing acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lameness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for antimicrobial treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in encopresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery from chronic constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: latency to the first postoperative flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: medical costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: knee-extensor strength at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in normal walking speed at week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time-to-progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of recurrence at day 92
Endpoint domain: Mortality/survival
Primary endpoint: Clinically relevant bleeding at day 92
Endpoint domain: Adverse events/effects
Primary endpoint: frames captured for esophageal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gastric examination time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma malondialdehyde (MDA) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gene expression of LDLR, IL-1, and TNF-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of ethanol in blood and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Repigmentation results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermatology Life Quality Index (DLQI) score reduction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: postoperative bleeding problems
Endpoint domain: Adverse events/effects
Primary endpoint: Use of antihypertensive drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean eGFR changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: VO2 levels during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Protective MenC-hSBA titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Umbilical artery pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Block height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemodynamic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enrollment of racial/ethnic minorities
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Verbal learning improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: General cognitive functioning improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: reduction in microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rhinorrhoea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pathological lateral pelvic lymph node metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mean adherence to antiretroviral therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in EQ-5D overall score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disease-free survival (DRFS)
Endpoint domain: Mortality/survival
Primary endpoint: emotional adjustment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: physical adjustment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: proportion of children with obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: World Health Organization‐5 Lowe score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: interphalangeal joint motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flexion contractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient engagement in medical dialog
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotional responses from patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: visual function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of falling
Endpoint domain: Adverse events/effects
Primary endpoint: visual disability improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Levels of CD62P
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of CD63
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Count of platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma free choline concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actual finish time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: left grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of short message service for medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum GLP-1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of gonorrhea, chlamydial infection, trichomoniasis, and BV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CCU (Condom Use)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social function
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mental component summary scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Colorectal cancer incidence
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of symptomatic hypoglycemia adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of vaginal deliveries of breech presentations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: 24-h post-transfusion survival values of autologous RBC
Endpoint domain: Mortality/survival
Primary endpoint: Post-exercise energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat oxidation during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of basophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Immunoglobin E levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in CMTNS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure (BP) normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Awareness of partner abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Additional life years gained
Endpoint domain: Mortality/survival
Primary endpoint: postoperative pain score with movement at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Task Specific Evaluation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Evaluation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean fractional ablation (NPV ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of massive gray-scale changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average sonication time to reach massive gray-scale changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily maximum post-operative pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative liver dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of healthcare-associated infections (HAI)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of bloodstream infections (BSI plus CABSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CTF (Cramps Tolerance Factor)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized mood scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: liver enzymes (alkaline phosphatase)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: marked improvement by subjective and objective assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproduction rate of EPNs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viability of EPNs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LD50 value of EPNs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: improvement in hold time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improved communication skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall life satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: induction to delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Bishop score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number delivered within 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in original body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased visceral adipose tissue (VAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased VAT:SAT ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decreased plasma lipoprotein lipase (LPL) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prolactin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean sEPCR concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean fTFPI increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: plasma levels of prothrombin fragment 1+2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain reduction during venipuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute reduction in the composite of cardiovascular death, MI, or stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depression remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to depression remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hospital Anxiety and Depression Scale (HADS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of cell adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of cell migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of cell invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate in patients with staphylococcal infections
Endpoint domain: Mortality/survival
Primary endpoint: Rate of serious postoperative S. aureus infections
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of multiorgan failure
Endpoint domain: Adverse events/effects
Primary endpoint: Complete response to canakinumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of disease flares
Endpoint domain: Adverse events/effects
Primary endpoint: Median CRP and SAA values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systolic pulmonary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: state anxiety sum score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: lumbar spine BMD loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV DNA response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALT sustained normalization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: executive function behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: small bowel transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: pain index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: bloating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Low back pain prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lower abdominal pain
Endpoint domain: Adverse events/effects
Primary endpoint: Shoulder tip pain
Endpoint domain: Adverse events/effects
Primary endpoint: CRF severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatigability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cumulative incidence of any adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of serious adverse events (SAE) excluding MS relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of hepatic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: WM0-60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum TSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BoP percentage decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mycological cure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: local progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Spontaneous return of circulation
Endpoint domain: Mortality/survival
Primary endpoint: 24-hour survival
Endpoint domain: Mortality/survival
Primary endpoint: maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the concentration-time curve (AUCt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of bacterial compositions on lesional skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CME by the fourth postoperative week
Endpoint domain: Adverse events/effects
Primary endpoint: anal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes